Related Experiment Video
Updated: Aug 5, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Neddylation cooperates with multiple phosphorylation to enhance FGFR1 stability and drive breast cancer progression
Yongjun Du1, Dezhou Ning1, Jing Yu1
1School of Medicine, Nankai University, Tianjin, 300071, China.
Background:
Fibroblast growth factor receptor 1 (FGFR1) is frequently overexpressed in breast cancer (BC), yet the mechanisms governing its protein stabilization remain unclear. This study investigates the role of neddylation, a ubiquitin-like modification, in sustaining FGFR1 levels and driving malignant progression in BC.
Methods:
The interaction between FGFR1 and the neddylation pathway was explored using clinical databases and experimental models. After characterizing FGFR1 neddylation via immunofluorescence and co-immunoprecipitation, we examined protein stability and signaling pathways following pharmacological (MLN4924) or genetic (NAE1 knockdown) neddylation inhibition. The therapeutic relevance was tested in BC cell lines and xenograft models, with its prognostic significance determined via bioinformatic tools.
Results:
Elevated FGFR1 significantly correlated with lymph node metastasis and reduced survival in patients. Core neddylation components, NAE1 and NEDD8, were upregulated in multiple breast cancer cell lines and essential for sustaining FGFR1 protein stability. Inhibiting neddylation induced FGFR1 degradation via the ubiquitin-proteasome system without altering mRNA levels. We identified a synergistic relationship between neddylation and FGFR1 phosphorylation that coordinately enhanced FGFR1 stabilization, activated downstream mTOR signaling, and suppressed Bax. Functionally, MLN4924 inhibited BC cell proliferation and migration, effects rescued by recombinant human FGF2 (rhFGF2) addition. In vivo, MLN4924 effectively suppressed tumor growth and reduced FGFR1/p-mTOR levels, mimicking the efficacy of the FGFR inhibitor Erdafitinib. Clinically, co-expression of FGFR1, NAE1, and NEDD8 predicted poor patient outcomes.
Conclusion:
These findings implicate the neddylation-FGFR1 axis as a critical oncogenic pathway in BC. Targeting this pathway represents a promising therapeutic strategy for patients with aberrant FGFR1 expression.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
